

**Date: 18<sup>th</sup> July 2023**

**BSE Limited**  
P J Towers,  
Dalal Street,  
Mumbai – 400 001

**National Stock Exchange of India Limited**  
Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051

**Script Code: 543904**

**Symbol: Mankind**

Dear Sir/ Madam,

**Subject: Intimation of Board Meeting under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

---

Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that a meeting of Board of Directors of the Company will be held on Wednesday, 2<sup>nd</sup> August 2023, inter-alia to consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter ended on 30<sup>th</sup> June 2023.

Further, in continuation of our earlier letter dated 29<sup>th</sup> June 2023 under subject 'Closure of Trading Window under SEBI (Prohibition of Insider Trading) Regulations, 2015 and the Company's 'Code of Conduct for Prevention of Insider Trading', the trading window for trading in the securities of the Company shall remain closed upto 48 hours after the declaration of unaudited standalone and consolidated financial results of the Company for the quarter ended on 30<sup>th</sup> June 2023.

The above notice and details are also being uploaded on the website of the Company at [www.mankindpharma.com](http://www.mankindpharma.com).

You are requested to kindly take the same on records.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited**

**Pradeep Chugh**  
**Company Secretary and Compliance Officer**  
**Membership No. A18711**

**MANKIND PHARMA LIMITED**